Activity Details

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Provider

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who are interested in the use of CAR T-cell therapy for the treatment of patients with hematologic malignancies.

Learning Objectives

After completing this activity, participants should be better able to:

• Review clinical trial data of current and emerging CAR T-cell therapies that are being investigated in patients with hematologic malignancies, including lymphoma, leukemia, and multiple myeloma
• Discuss the potential for using CAR T-cell-based therapies in patients with other malignancies
• Discuss common adverse events that are associated with CAR T-cell therapy, and develop strategies to mitigate such adverse events

Activity Description

Podium to Practice is a discussion among two renowned experts actively engaged in clinical trials and the management of patients with CAR T cells. This exchange features expert summary and interpretation of data presented during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, and provides guidance on the optimal use of CAR T cells for patients with hematologic malignancies.

Statement of Educational Need

CAR T cells have emerged as a highly effective therapy in patients with hematologic malignancies and show promise in patients with solid tumors. However, multiple CAR T technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with these agents need expert guidance to evaluate clinical data of CAR T therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.

Faculty

Matthew Lunning, DO - Moderator
Associate Professor
Internal Medicine
Division of Oncology & Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Consulting Fees: AbbVie, Inc., Bayer, Celgene Corporation, DAVA, Gilead Sciences, Inc., Janssen, Juno Therapeutics, Kite Pharma, Novartis, OncLive, Portola, Seattle Genetics, Spectrum Pharmaceuticals, TG Therapeutics, Vaniam Group, Verastem
Grants/Research Support: Celgene Corporation, Curis, Janssen Scientific Affairs, LLC, Juno Therapeutics, MiRagen, TG Therapeutics

Reem Karmali, MD, MS
Assistant Professor
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

Advisory Board: Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma
Grants/Research Support: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma, Takeda Pharmaceutical Company Ltd
Speakers Bureau: Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma

Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

This program may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250

Bio Ascend
cme@bioascend.com